Why Viatris Inc. (VTRS) stock moved
No significant move on Nov 20, 2026 (−1.3%, close-to-close). Latest notable session: Nov 9, 2026.
Why Viatris Inc. (VTRS) rose 2.9% on November 9, 2026
Viatris Inc. (VTRS) rose 2.9% on November 9, 2026, closing at $20.49 versus $19.91 the prior session (close-to-close, from daily closes). Viatris posted third-quarter adjusted EPS of $0.71, beating consensus of $0.64, and raised full-year 2026 guidance to $2.59 adjusted EPS and $4.5 billion adjusted EBITDA (per investor.viatris.com). The stock gained 2.76% to $20.46 on normal volume (1.05x average). Source: investor.viatris.com.
Viatris posted third-quarter adjusted EPS of $0.71, beating consensus of $0.64, and raised full-year 2026 guidance to $2.59 adjusted EPS and $4.5 billion adjusted EBITDA (per investor.viatris.com). The stock gained 2.76% to $20.46 on normal volume (1.05x average).
What to watch next: Pacira BioSciences acquisition closing (targeted late November 2026) and next earnings report scheduled for 2027-02-25.
Earlier sessions that moved VTRS
- +5.0%Viatris filed an earnings report and material event (8-K) today, lifting the stock +2.24% to $19.39.
- −1.3%Viatris Inc. (VTRS) reported EPS of $0.71 vs. consensus estimate of $0.64, beating by 11.5% on 2026-11-05.
- +4.5%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −3.3%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Viatris Inc. (VTRS) shares fell 1.3% to $19.63 as of November 21, 2026, a modest decline from the prior close of $19.88. BestStocks flagged the session as a major change for VTRS. The move is tied to company news. Below, we break down what changed for VTRS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Viatris completed its acquisition of Pacira BioSciences, a non-opioid pain management leader. Acquisition expands Viatris's specialty pharmaceutical portfolio and non-opioid pain treatment capabilities.
What it means for Viatris Inc. investors
For Viatris Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Viatris filed an earnings report and material event (8-K) today, lifting the stock +2.24% to $19.39; Positive price momentum. Weighing against that: Negative session, down 1.3%; VTRS moved -10.25% from its $18.15 open to a $16.29 close on 2026-08-06. Wall Street's consensus price target sits at $21.00, implying +7.0% upside from $19.63. BestStocks rates the overall signal quality weak (39/100). With earnings roughly 96 days out, the next report is the most likely near-term test of the move.
VTRS price reaction
VTRS last traded at $19.63, down $0.25 (-1.26%) from the previous close of $19.88. The session traded on 1.0× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Viatris Inc. (VTRS)
The consensus analyst price target on Viatris Inc. (VTRS) is $21.00, 7.0% above the recent $19.63. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on VTRS line up.
The bullish case
- Wall Street's consensus price target of $21.00 implies +7.0% upside from $19.63.
- The Street's most bullish target is $26.00 (+32.5%).
- Viatris filed an earnings report and material event (8-K) today, lifting the stock +2.24% to $19.39.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $14.00 (-28.7%).
- Negative session, down 1.3%.
- VTRS moved -10.25% from its $18.15 open to a $16.29 close on 2026-08-06.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for VTRS
Frequently asked questions about VTRS
Why did Viatris Inc. (VTRS) stock move?
Viatris Inc. (VTRS) rose 2.9% on November 9, 2026, closing at $20.49 versus $19.91 the prior session (close-to-close, from daily closes). Viatris posted third-quarter adjusted EPS of $0.71, beating consensus of $0.64, and raised full-year 2026 guidance to $2.59 adjusted EPS and $4.5 billion adjusted EBITDA (per investor.viatris.com). The stock gained 2.76% to $20.46 on normal volume (1.05x average). Source: investor.viatris.com.
How much did VTRS stock fall?
VTRS lost 1.26% ($0.25) versus the prior close of $19.88, last trading at $19.63 on 1.0× average volume.
When is Viatris Inc.'s next earnings date?
VTRS's next earnings report is estimated for 2027-02-25 — about 96 days away.
What is the analyst price target for VTRS?
The consensus analyst price target for VTRS is $21.00, about 7.0% above the current $19.63. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks VTRS
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for VTRS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
